GPRC5D Protein-Nanodisc, Cynomolgus (HEK293, His, Flag)

G 蛋白偶联受体仅存在于真核生物中，包括酵母和鞭藻。结合并激活这些受体的配体包括光敏化合物、气味、信息素、激素和神经递质，其大小从小分子到多肽再到大蛋白质不等。G 蛋白偶联受体与许多疾病有关。G 蛋白偶联受体的信号转导途径包括 cAMP 信号通路和磷脂酰肌醇信号通路。GPRC5D 是一种偶联 G 蛋白的孤儿受体，与哺乳动物 G 蛋白偶联受体 (GPCRs) 超家族 C 家族第五组成员 (与代谢性谷氨酸受体样相关) 具有同源性。GPRC5D 是 CAR-T 细胞免疫治疗多发性骨髓瘤的靶点 GPRC5D Protein-Nanodisc, Cynomolgus (HEK293, His, Flag) is the recombinant cynomolgus-derived GPRC5D protein, expressed by HEK293, with C-His and N-Flag labeled tag.

G protein-coupled receptor class C 5 member D (GPRC5D) is a G protein-coupled orphan receptor that shares homology with mammalian G protein-coupled receptors (GPCRs) superfamily C family group 5 member (related to metabotropic glutamate receptor-like) and belongs to the RAIG1 family along with two highly homologous orphan G protein-coupled receptors (oGPCRs), GPRC5B and GPRC5C (RAIG1 was originally isolated as an orphan GPCR by differential display, and its expression can be induced by all-trans retinoic acid (ATRA) in human head and neck squamous cell carcinoma (HNSCC)). As a member of the G protein-coupled receptor that only exists in eukaryotes (including yeast and flagella), GPRC5D is mainly expressed on malignant plasma cells, but limitedly expressed in normal tissues. It is a potential therapeutic target for relapsed/refractory multiple myeloma (R/R MM). Its targeted CAR-T, CAR-NK cell therapy and bispecific T cell engagers have significant anti-tumor activity, and it is also a target for CAR-T cell immunotherapy of multiple myeloma. In addition, G protein-coupled receptors can be bound and activated by a variety of ligands (ranging in size from small molecules to large proteins), such as photosensitive compounds, odors, and hormones, and are associated with a variety of diseases. Its signal transduction pathways include the cAMP signaling pathway and the phosphatidylinositol signaling pathway.

Cynomolgus

HEK293

C-His;N-Flag

A0A2K5W6I7 (M1-F192)&(E191-L262)

102122120

Approximately 37 kDa, based on SDS-PAGE under reducing conditions.

Greater than 80% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.

• [1]. Smith EL, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485):eaau7746.  [Content Brief]

  [2]. King N, et al. Evolution of key cell signaling and adhesion protein families predates animal origins. Science. 2003 Jul 18;301(5631):361-3.  [Content Brief]

  [3]. Gilman AG. G proteins: transducers of receptor-generated signals. Annu Rev Biochem. 1987;56:615-49.  [Content Brief]